Chemoinformaics analysis of 3(2H)-Furanone, 5-methyl-2-octyl-
| Molecular Weight | 210.317 | nRot | 7 |
| Heavy Atom Molecular Weight | 188.141 | nRig | 5 |
| Exact Molecular Weight | 210.162 | nRing | 1 |
| Solubility: LogS | -4.27 | nHRing | 1 |
| Solubility: LogP | 5.133 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 37 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 13 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 37.9834 |
| nHD | 0 | BPOL | 24.6746 |
| QED | 0.684 |
| Synth | 2.428 |
| Natural Product Likeliness | 0.561 |
| NR-PPAR-gamma | 0.546 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.004 |
| HIA | 0.003 |
| CACO-2 | -4.666 |
| MDCK | 0.0000181 |
| BBB | 0.67 |
| PPB | 0.977072 |
| VDSS | 3.737 |
| FU | 0.0265409 |
| CYP1A2-inh | 0.962 |
| CYP1A2-sub | 0.846 |
| CYP2c19-inh | 0.794 |
| CYP2c19-sub | 0.491 |
| CYP2c9-inh | 0.466 |
| CYP2c9-sub | 0.956 |
| CYP2d6-inh | 0.446 |
| CYP2d6-sub | 0.869 |
| CYP3a4-inh | 0.265 |
| CYP3a4-sub | 0.175 |
| CL | 8.661 |
| T12 | 0.529 |
| hERG | 0.012 |
| Ames | 0.077 |
| ROA | 0.121 |
| SkinSen | 0.522 |
| Carcinogencity | 0.057 |
| EI | 0.967 |
| Respiratory | 0.7 |
| NR-Aromatase | 0.686 |
| Antiviral | Yes |
| Prediction | 0.681893 |